BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35674078)

  • 1. Is calcitonin gene-related peptide a reliable biochemical marker of migraine?
    Tesfay B; Karlsson WK; Moreno RD; Hay DL; Hougaard A
    Curr Opin Neurol; 2022 Jun; 35(3):343-352. PubMed ID: 35674078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls.
    Kamm K; Straube A; Ruscheweyh R
    Cephalalgia; 2019 Oct; 39(12):1535-1543. PubMed ID: 31603037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
    Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
    Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine.
    Cernuda-Morollón E; Larrosa D; Ramón C; Vega J; Martínez-Camblor P; Pascual J
    Neurology; 2013 Oct; 81(14):1191-6. PubMed ID: 23975872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin and Neuropeptides in Blood From Episodic and Chronic Migraine and Cluster Headache Patients in Case-Control and Case-Crossover Settings: A Systematic Review and Meta-Analysis.
    Frederiksen SD; Bekker-Nielsen Dunbar M; Snoer AH; Deen M; Edvinsson L
    Headache; 2020 Jun; 60(6):1132-1164. PubMed ID: 32293721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathophysiological role of calcitonin gene-related peptide (CGRP) in migraine and cluster headache].
    Meßlinger K
    Schmerz; 2020 Apr; 34(2):181-187. PubMed ID: 32103345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine.
    Ramón C; Cernuda-Morollón E; Pascual J
    Curr Opin Neurol; 2017 Jun; 30(3):281-286. PubMed ID: 28234796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review.
    Tfelt-Hansen P; Le H
    J Headache Pain; 2009 Jun; 10(3):137-43. PubMed ID: 19330286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-calcitonin gene-related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache.
    Kang SA; Govindarajan R
    Muscle Nerve; 2021 Apr; 63(4):563-567. PubMed ID: 33347632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks: A Randomized Clinical Trial.
    Vollesen ALH; Snoer A; Beske RP; Guo S; Hoffmann J; Jensen RH; Ashina M
    JAMA Neurol; 2018 Oct; 75(10):1187-1197. PubMed ID: 29987329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal.
    Lee MJ; Lee SY; Cho S; Kang ES; Chung CS
    J Headache Pain; 2018 Jul; 19(1):53. PubMed ID: 30006780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galcanezumab effectiveness on comorbid cluster headache and chronic migraine: a prospective case series.
    Iannone LF; Fattori D; Geppetti P; De Cesaris F
    Neurol Sci; 2022 Jan; 43(1):697-703. PubMed ID: 34586542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.
    Schuster NM; Rapoport AM
    Clin Neuropharmacol; 2017; 40(4):169-174. PubMed ID: 28644160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.
    Khan S; Olesen A; Ashina M
    Cephalalgia; 2019 Mar; 39(3):374-389. PubMed ID: 29110503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CGRP in human models of primary headaches.
    Ashina H; Schytz HW; Ashina M
    Cephalalgia; 2018 Feb; 38(2):353-360. PubMed ID: 27940880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of anti-CGRP antibodies in the pathophysiology of primary headaches.
    Barbanti P; Aurilia C; Fofi L; Egeo G; Ferroni P
    Neurol Sci; 2017 May; 38(Suppl 1):31-35. PubMed ID: 28527063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond CGRP: The calcitonin peptide family as targets for migraine and pain.
    Rees TA; Hendrikse ER; Hay DL; Walker CS
    Br J Pharmacol; 2022 Feb; 179(3):381-399. PubMed ID: 34187083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can calcitonin gene-related peptide (CGRP) and pentraxin-3 (PTX-3) be useful in diagnosing acute migraine attack?
    Vural S; Albayrak L
    J Recept Signal Transduct Res; 2022 Dec; 42(6):562-566. PubMed ID: 35895308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan.
    Cady RK; Vause CV; Ho TW; Bigal ME; Durham PL
    Headache; 2009 Oct; 49(9):1258-66. PubMed ID: 19788468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.